Promescent specializes in premature ejaculation treatment, particularly their FDA-compliant delay spray. They focus exclusively on sexual wellness products for men.
We earn commissions from brands listed on this site, which influences how listings are presented. Advertising Disclosure


Complete 2026 Comparison for Premature Ejaculation
Mate is our overall pick for premature ejaculation, based on ratings, reviews, and feature coverage. Promescent has the larger review base.
Promescent specializes in premature ejaculation treatment, particularly their FDA-compliant delay spray. They focus exclusively on sexual wellness products for men.
Mate (GoodnightMate) specializes in premature ejaculation treatment, offering prescription and OTC solutions designed to help men last longer.
| Feature | ||
|---|---|---|
| Rating | 9/10 | 9/10 |
| Reviews | 11,200 | 8,400 |
| Founded | 2013 | 2020 |
| Free Consultation | No | Yes |
| Free Shipping | Yes | Yes |
| Accepts Insurance | No | No |
| HSA/FSA Accepted | No | Yes |
| Mobile App | No | No |
| Consultation Type | No consultation (OTC products) | Asynchronous |
| Shipping Time | 2-5 business days | 3-5 business days |
| Treatment | ||
|---|---|---|
| Premature Ejaculation | $22.95$22.95-$89.95 | $35/month$35-$95/month |
The better choice depends on your specific needs and priorities. Promescent carries a 8.4/10 rating in our provider database and is listed as a fit for men with premature ejaculation. Mate carries a 9.2/10 rating in our provider database and is listed as a fit for men specifically seeking pe treatment. Those scores are our own editorial ratings, not third-party review averages. Promescent was founded in 2013 in Las Vegas, NV, while Mate was founded in 2020 in Austin, TX. Both are US telehealth platforms that connect you with licensed providers, and which one suits you is a question for that provider.
Pricing varies by treatment category. Promescent starts at $22.95 (range: $22.95-$89.95). Mate starts at $35/month (range: $35-$95/month). These are the rates last recorded in our provider database, so confirm the current price at checkout before you enroll. Mate lists free consultations. Promescent lists free shipping. Mate lists free shipping. Mate list HSA and FSA payment options, though whether a given charge is eligible depends on your plan and on IRS rules for that expense.
Promescent does not list health insurance as accepted, and operates on a cash-pay model with published pricing. Mate does not list insurance as accepted. Mate list HSA and FSA payment options; eligibility for any specific charge depends on your plan and IRS rules, so check with your plan administrator first. Coverage and pricing change, so confirm both with the platform and your insurer before you enroll.
Both are established US telehealth platforms. Promescent was founded in 2013 and is headquartered in Las Vegas, NV. Mate was founded in 2020 in Austin, TX. Both state that they work with US-licensed providers and licensed pharmacies and that they operate under HIPAA. We do not independently audit provider credentials or pharmacy licensing, so if you want that confirmed, you can look up an individual prescriber through your state medical board and a pharmacy through your state board of pharmacy.
Promescent offers no consultation (otc products) consultations. Mate provides asynchronous consultations (free). On both, you complete a health questionnaire online that a licensed provider reviews. Turnaround times vary by platform, by state, and by how busy the provider network is, and you can message your provider with follow-up questions through the platform.
Promescent lists shipping within 2-5 business days with free standard shipping. Mate lists shipping within 3-5 business days with free standard shipping. Both describe discreet packaging, and medications ship from licensed pharmacies rather than from the platform itself. Actual delivery time depends on your state, the pharmacy, and whether your prescription needs follow-up.
Promescent offers both subscription and one-time purchase options and lists cancellation at any time without a fee. Mate also uses a subscription model and lists no cancellation penalty. Cancellation terms are set by each platform and can change, so read the current terms before you enroll. As a general rule you need to cancel before your next billing date to avoid the following period's charge, and anything already shipped is still yours.
Promescent lists Delay Spray, Climax Control Spray, Desensitizing Wipes starting at $22.95. Mate lists Prescription PE Medication, Topical Treatments, Combination Therapy starting at $35/month. Common approaches are an SSRI such as sertraline, which is prescribed off-label for premature ejaculation and is not FDA-approved for that use, and topical numbing sprays or creams containing lidocaine or benzocaine. What you can compare here is price, format, and whether a prescription is involved. Which approach fits your situation, and whether an off-label prescription makes sense for you, is a decision for a licensed provider.
Side effects come from the medication, not from the platform, so this is mostly a question about the drug you end up on rather than about Promescent versus Mate. Reported effects vary by treatment: ED medications may cause headache, flushing, or nasal congestion; finasteride carries labeled sexual side effects that some men report persisting after they stop; GLP-1 medications commonly cause nausea, vomiting, and other gastrointestinal effects, especially when the dose goes up; SSRIs may cause drowsiness, nausea, or changes in appetite and sexual function. This is not the full list for any of them. Both platforms have licensed providers review your medical history and screen for contraindications, and you should read the medication guide and raise anything you notice with your provider.
Choose Promescent if you prioritize: men with premature ejaculation, those preferring otc solutions. Choose Mate if you prioritize: men specifically seeking pe treatment, those wanting prescription options. Promescent stands out for: PE specialist focus. Mate is known for: PE treatment specialist. Both are established telehealth platforms, so your choice mostly comes down to price, which treatments each one carries, and how you prefer to handle visits and refills.
The process is similar on both. For Promescent: visit their website, select your treatment category, and complete a health questionnaire that a licensed provider reviews. For Mate: follow the same kind of flow on their platform. Both ask for your medical history, current medications, and answers to health screening questions, and being straight with those answers is what lets the provider catch an interaction. If you are approved, the prescription goes to a licensed pharmacy and ships to you (often with free shipping). How long the whole thing takes depends on the platform, your state, and the pharmacy.
Promescent carries a 8.4/10 rating in our provider database, and Mate carries a 9.2/10 rating in our provider database. Those are ManyTreatments editorial scores on a 10-point scale, not averages pulled from third-party review sites, and you can read how we build them on our how-we-rate page. What we weigh: Promescent scores well on no prescription required, with only addresses pe as the trade-off. For Mate it is pe specialist focus, against only treats pe. If you want customer sentiment as well, check current listings on the review platforms directly, since those move.
Medical Disclaimer: The information on this page is for educational purposes only and is not medical advice. Always consult with a licensed healthcare provider before starting any treatment. Read our full medical disclaimer.
Regulatory noticeRegulatory note (verified August 22, 2026): On September 9, 2025 the FDA sent Hims & Hers Health, Inc. a warning letter covering the Hims brand, MARCS-CMS 716567, drawn from a review of hims.com the previous month. Two lines about compounded semaglutide are quoted in it: "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." Compounded drug products are not FDA-approved, and the agency said phrasing of this sort suggests otherwise, which is what makes the products misbranded under FD&C Act sections 502(a) and 502(bb). A companion letter went to the same company that day for its Hers brand. No close-out letter appears in FDA’s index; treat this as open. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): The FDA reviewed struthealth.com in December 2025 and, on February 20, 2026, issued Strut Health, LLC a warning letter, MARCS-CMS 721448. It raises two separate problems. Pictured product labels carry the "Strut" name, which the agency said represents Strut as the compounder of the semaglutide and tirzepatide products when it is not. Three site claims are also quoted, among them "Generic Zepbound, Mounjaro" and "Semaglutide is the active ingredient in the brand medications." Because compounded drugs hold no FDA approval, the FDA said wording of that kind implies one, and it cited misbranding under sections 502(a) and 502(bb) of the FD&C Act. FDA’s warning letter index shows no response letter and no close-out letter, so we treat the matter as open. Read the FDA letter